Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Assist Reprod Genet. 2007 Dec;24(12):629-34. Epub 2007 Dec 11.

Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function.

Author information

1
Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. dbarad@thechr.com

Abstract

OBJECTIVE:

We assessed the role of DHEA supplementation on pregnancy rates in women with diminished ovarian function.

DESIGN:

This is a case control study of 190 women with diminished ovarian function. The study group includes 89 patients who used supplementation with 75 mg daily of oral, micronized DHEA for up to 4 months prior to entry into in vitro fertilization (IVF). The control group is composed of 101 couples who received infertility treatment, but did not use DHEA. The primary outcome was clinical pregnancy after the patient's initial visit. We developed a Cox proportional hazards model to compare the proportional hazards of pregnancy among women using DHEA with the controls group.

RESULTS:

Cumulative clinical pregnancy rates were significantly higher in the study group (25 pregnancies; 28.4% vs. 11 pregnancies; 11.9%; relative hazard of pregnancy in study group (HR 3.8; 95% CI 1.2-11.8; p < 0.05).

CONCLUSIONS:

DHEA treatment resulted in significantly higher cumulative pregnancy rates. These data support a beneficial effect of DHEA supplementation among women with diminished ovarian function.

PMID:
18071895
PMCID:
PMC3454995
DOI:
10.1007/s10815-007-9178-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center